TTR and hypertrophic cardiomyopathy: These findings were replicated in the MSHS cohort, for which our model achieved an AUROC curve of up to 0·890 (95% CI 0·839–0·938) for hypertrophic cardiomyopathy (apical-4-chamber), and 0·994 (0·992–0·996) and 0·972 (0·959–0·983) for parasternal long-axis and parasternal short-axis-based screening of transthyretin amyloid cardiomyopathy, respectively (table 2; appendix p 8).